Summary of Arvinas Q3 2025 Earnings Call

1Key Financial Results and Metrics

Cash Position: As of September 30, 2025, Arvinas reported approximately $787.6 million in cash, cash equivalents, and marketable securities, down from $1.04 billion at the end of 2024.

Revenue: Q3 2025 revenue totaled $41.9 million, a decrease from $102.4 million in Q3 2024, primarily due to the conclusion of revenue recognition from a Novartis license agreement, offset by a $20 million milestone payment from Novartis.

Expenses: General and administrative expenses were $21 million, significantly reduced from $75.8 million in the prior year, largely due to the termination of a lease and reduced personnel costs. Research and development expenses were $64.7 million, down from $86.9 million year-over-year.

Stock Repurchase: The Board authorized a $100 million stock repurchase program, with approximately 2.56 million shares repurchased at an average price of $7.91 per share.

2Strategic Updates and Business Highlights

Pipeline Progress: Arvinas highlighted significant advancements in its clinical pipeline, including promising data from ARV-102 (LRRK2 degrader) and ARV-393 (BCL6 degrader). The company is also advancing ARV-806 (KRAS G12D degrader) and ARV-027 (targeting polyQ-AR) into clinical trials.

Partnerships: Arvinas is collaborating with Pfizer to select a third party for the commercialization of vepdegestrant, which is under FDA review with a PDUFA date of June 5, 2026.

Upcoming Data: The company anticipates multiple data readouts in the coming months, including presentations at major conferences.

3Forward Guidance and Outlook

Financial Guidance: Arvinas expects to maintain a quarterly run rate below $75 million in expenses, aiming for total non-GAAP expenses below $300 million in fiscal year 2026. The cash runway is projected to extend into the second half of 2028.

Clinical Development Plans: The company plans to initiate a Phase Ib trial for ARV-102 in progressive supranuclear palsy (PSP) in the first half of 2026 and is preparing for additional trials for its other candidates.

4Bad News, Challenges, or Points of Concern

Revenue Decline: The significant drop in revenue year-over-year raises concerns about the company’s financial health and reliance on milestone payments.

Clinical Development Risks: While early data for several candidates are promising, the company has not yet achieved predicted efficacious exposure levels in ongoing trials, particularly for ARV-393.

Market Competition: The competitive landscape for oncology and neurology therapeutics is intensifying, with several companies developing similar PROTAC technologies, which could pressure Arvinas' market position.

5Notable Q&A Insights

ARV-393 Differentiation: The management emphasized the potential for ARV-393 to differentiate itself in the market, particularly in combination therapies for non-Hodgkin lymphoma.

ARV-102 Expectations: Questions regarding the LRRK2 program highlighted the importance of biomarker data in translating to clinical benefits, with expectations for significant reductions in biomarkers associated with neurodegeneration.

Combination Strategies: The company is exploring combination therapies for ARV-806 and is optimistic about the potential for these combinations to enhance therapeutic efficacy while minimizing toxicity.

HPK1 Program: There is enthusiasm around the HPK1 degrader, with expectations for more preclinical data to be shared soon, indicating its potential in immuno-oncology. Overall, Arvinas is navigating a dynamic period with a strong pipeline and strategic partnerships, but faces challenges in revenue generation and competitive pressures in the biotech landscape.